UBS AM’s Candel Therapeutics CADL Stock Holding History

UBS AM’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42K	Hold	138	–	–	﹤0.01%	3585
2026 Q1	$676	Buy	+138	New	+$751	﹤0.01%	3709

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM's CADL Position: Q2 2026 in Review

UBS AM held its Candel Therapeutics (CADL) position steady in Q2 2026 at 138 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #3585.

UBS AM first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

UBS AM held 138 shares of Candel Therapeutics worth $1.42K as of Q2 2026.
UBS AM left its Candel Therapeutics share count unchanged in Q2 2026.
Candel Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3585 holding.
UBS AM first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.